Physician profile
Barbara Houde
NPI 1417997883
$6,945.19
in general payments reported to CMS, 2019-2025
19 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $472 · 2021: $690 · 2022: $256 · 2023: $1,092 · 2024: $1,579 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,841.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,076.28 | 2022-2025 | Vyzulta, Miebo, Infuse |
| Sun Pharmaceutical Industries INC. | $937.34 | 2019-2025 | Cequa |
| Allergan, INC. | $816.35 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $725.05 | 2019-2021 | |
| Abbvie INC. | $659.67 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $539.86 | 2019-2021 | |
| Alcon Vision LLC | $467.99 | 2023-2025 | Simbrinza, Hydrus Microstent, Rocklatan |
| Glaukos Corporation | $334.44 | 2025 | Idosetr |
| Oyster Point Pharma, INC. | $322.90 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $282.57 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $232.17 | 2023 | Syfovre |
| Kala Pharmaceuticals, INC. | $122.06 | 2021 | |
| Thea Pharma INC. | $120.91 | 2023-2025 | Iyuzeh |
| Astellas Pharma US INC | $106.77 | 2024 | Izervay |
| Johnson & Johnson Vision Care, INC. | $83.56 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $38.33 | 2021 | |
| Lombart Brothers, INC. | $30.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.18 | 2019 | |
| Harrow Eye, LLC | $23.50 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Houde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.